Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A DDR milestone
April 2018
SHARING OPTIONS:

CAMBRIDGE, U.K.—March saw Artios Pharma announce the exercising of its option to in-license the first nuclease drug development program under its research collaboration and option agreement with Masaryk University in the Czech Republic. The companies began their collaboration last June, with the aim of discovering and developing novel cancer treatments by targeting DNA nucleases that play a role in the DNA damage response (DDR).
 
“We are extremely pleased that Artios has chosen to in-license the lead nuclease research program under our strategic collaboration, and I am very proud of our team here at Masaryk University. We believe nucleases have the potential to provide a new wave of innovative DDR-based cancer therapies and are confident in Artios’ ability to translate this program to the clinic to benefit the lives of cancer patients,” commented Dr. Lumir Krejci, principal investigator on DDR nucleases at Masaryk University.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.